Propentofylline after focal cortical lesion in the rat: impact on functional recovery and basic fibroblast growth factor expression.
The effects of propentofylline, a xanthine derivative and adenosine transport inhibitor, were evaluated following anteromedial cortex lesion in the rat. Propentofylline (2x/10 mg/kg, intraperitoneally) was administered for 7 days post-insult and basic fibroblast growth factor (bFGF) immunoreactivity measured at designated time points in the peri-lesional cortex and ipsilateral dorsal striatum. The spatiotemporal pattern of bFGF expression was then compared to functional recovery patterns. Propentofylline-treated animals displayed increased bFGF expression in the peri-lesional cortex which may have contributed to the observed early facilitation of functional recovery. Drug administration did not, however, produce a change in bFGF expression in the ipsilateral dorsal striatum compared to saline-treated animals. These findings taken together with other positive findings regarding propentofylline, support the drug's therapeutic potential.
Buytaert-Hoefen
Kimberley A
KA
UCHSC, Department of Clinical Pharmacology, Campus Box C237, 4200 East 9th Avenue, Denver, CO 80262, USA.
Kreber
Lisa A
LA
Millar
Courtney J
CJ
Walsh
Uriah T
UT
Brannigan
Chris
C
Hernandez
Theresa D
TD
D000818:Animals; D001253:Astrocytes / Q000187:drug effects / Q000378:metabolism; D001930:Brain Injuries / Q000188:drug therapy*; D002540:Cerebral Cortex / Q000187:drug effects* / Q000293:injuries / Q000378:metabolism / Q000503:physiopathology; D016222:Fibroblast Growth Factor 2 / Q000096:biosynthesis*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D051381:Rats; D020318:Rats, Long-Evans; D020127:Recovery of Function; D014970:Xanthines / Q000627:therapeutic use*
D018696:Neuroprotective Agents; D014970:Xanthines; D016222:Fibroblast Growth Factor 2; C032114:propentofylline